Date: 2015-12-05
Type of information: Series C financing round
Company: Allena Pharmaceuticals (USA - MA)
Investors:
Amount: $53 million
Funding type: series C financing round
Planned used:
- Allena intends to use the proceeds from the financing to advance its lead product candidate, ALLN-177 for the treatment of secondary hyperoxaluria in patients with a history of calcium oxalate kidney stones, into Phase 3 clinical trials. The proceeds will also be used to explore additional indications for ALLN-177, including oxalate nephropathy and primary hyperoxaluria, and to develop new product candidates utilizing Allena’s non-systemic oral protein therapeutic platform.
- Building upon the prior successful completion of Phase 1 and Phase 2a trials, Allena is presently conducting two additional Phase 2 trials of ALLN-177 in the United States for calcium oxalate kidney stone patients with hyperoxaluria. The first trial is a double-blind, placebo-controlled crossover dose-ranging study (NCT02503345). The second trial is a double-blind, placebo-controlled parallel design study of 28 days duration (NCT02547805).
Others:
- • On December 9, 2015; Allena Pharmaceuticals announced the successful completion of a $53 million Series C financing. The Series C financing was led by Partner Fund Management and included additional new investors Fidelity Management & Research Company and Wellington Management Company. Allena’s existing investors, Frazier Healthcare, HBM BioCapital, and Pharmstandard International, S.A. also participated in the financing. Allena has raised a total of $96 million in private equity financing to date.
Therapeutic area:
Is general: Yes
